ERAS News & Analysis

Erasca (ERAS) Stock Buy Rating Reiterated by Jefferies Ahead of ASCO

Jefferies has reiterated a Buy rating for Erasca (ERAS) stock in anticipation of upcoming data from the American Society of Clinical Oncology (ASCO) meeting. The firm supports its recommendation, suggesting confidence in future developments for ERAS. This reiteration could influence investor sentiment positively as the meeting approaches. Analysts typically use such ratings to guide purchasing decisions and assess potential market movement.